Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-β
Marina Ostroukhova, Zengbiao Qi, Timothy B. Oriss, Barbara Dixon-McCarthy, rabir Ray,, Anuradha Ray
Marina Ostroukhova, Zengbiao Qi, Timothy B. Oriss, Barbara Dixon-McCarthy, rabir Ray,, Anuradha Ray
View: Text | PDF
Research Article Immunology

Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-β

  • Text
  • PDF
Abstract

Studies in humans and mice show an important role for Tregs in the control of immunological disorders. The mechanisms underlying the immunosuppressive functions of Tregs are not well understood. Here, we show that CD4+ T cells expressing Foxp3 and membrane-bound TGF-β (TGF-βm+Foxp3+), previously shown to be immunosuppressive in both allergic and autoimmune diseases, activate the Notch1–hairy and enhancer of split 1 (Notch1-HES1) axis in target cells. Soluble TGF-β and cells secreting similar levels of soluble TGF-β were unable to trigger Notch1 activation. Inhibition of Notch1 activation in vivo reversed the immunosuppressive functions of TGF-βm+Foxp3+ cells, resulting in severe allergic airway inflammation. Integration of the TGF-β and Notch1 pathways may be an important mechanism for the maintenance of immune homeostasis in the periphery.

Authors

Marina Ostroukhova, Zengbiao Qi, Timothy B. Oriss, Barbara Dixon-McCarthy, rabir Ray,, Anuradha Ray

×

Figure 6

Membrane-bound TGF-β, but not soluble TGF-β, induces interaction between cleaved Notch1 and pSmad3.

Options: View larger image (or click on image) Download as PowerPoint
Membrane-bound TGF-β, but not soluble TGF-β, induces interaction between...
DO11.10 CD4+ T cells were cocultured with TGF-βm+ cells, TGF-βm– cells, naive CD4+ T cells, or soluble TGF-β (2 ng/ml) for 24 hours, and cell extracts were prepared. The extracts were subjected to immunoprecipitation using anti-pSmad3 or isotype control (with TGF-βm+ cells). The immunoprecipitates were analyzed by immunoblotting with antibody against cleaved Notch1, and the blot was stripped and reprobed with anti-pSmad3. While all lysates contained similar levels of Smad3, which is constitutively expressed in cells (data not shown), Smad3 was phosphorylated in the presence of TGF-βm+ cells, TGF-βm– cells, or soluble TGF-β, but not naive cells.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts